Short Interest in Jaguar Health, Inc. (NASDAQ:JAGX) Increases By 11.4%

Jaguar Health, Inc. (NASDAQ:JAGX) was the recipient of a large growth in short interest in September. As of September 30th, there was short interest totalling 413,000 shares, a growth of 11.4% from the September 15th total of 370,700 shares. Based on an average daily trading volume, of 717,100 shares, the days-to-cover ratio is currently 0.6 days. Approximately 5.3% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Jaguar Health from a “sell” rating to a “hold” rating in a report on Friday, September 13th.

Jaguar Health Stock Up 6.0 %

JAGX stock opened at $1.23 on Thursday. Jaguar Health has a twelve month low of $0.95 and a twelve month high of $30.86. The business has a 50 day moving average price of $1.17 and a two-hundred day moving average price of $4.68. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.60 and a current ratio of 2.10.

Jaguar Health (NASDAQ:JAGX) last released its earnings results on Tuesday, August 13th. The biotechnology company reported ($4.04) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($2.84). The firm had revenue of $2.72 million during the quarter. Jaguar Health had a negative net margin of 350.18% and a negative return on equity of 412.63%. On average, sell-side analysts predict that Jaguar Health will post -0.78 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Jaguar Health stock. Perritt Capital Management Inc bought a new stake in Jaguar Health, Inc. (NASDAQ:JAGX) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 25,000 shares of the biotechnology company’s stock, valued at approximately $90,000. Perritt Capital Management Inc owned about 0.51% of Jaguar Health as of its most recent filing with the Securities and Exchange Commission. 12.04% of the stock is currently owned by hedge funds and other institutional investors.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.